GSK plc announced on January 7, 2025, that its drug GSK'227, targeting relapsed osteosarcoma, has received US FDA Breakthrough Therapy Designation, highlighting its potential to improve treatment for this serious condition with no approved therapies after two prior treatments. The trial involved over 60 patients, with 42 specifically suffering from osteosarcoma, indicating a significant medical need.